Long-Acting Injectables Patient Advisory Committee
Quick links
ADAP Advocacy is currently recruiting patients and public health stakeholders to serve on its Long-Acting Injectables Patient Advisory Committee.
BACK TO ADVISORY COMMITTEESCommittee Members
The committee is open to adding new discussion topics to its meeting agenda. Click here to submit your thoughts to Warren O’Meara-Dates, chair of the Long-Acting Injectables Patient Advisory Committee.
May 7, 2026
April 28, 2025
BACK TO TOPCommittee Meetings
U.S. Food & Drug Administration (FDA)
Yeztugo Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection (June 18, 2025)*
FDA Approves Sunlenca for Adults With Resistant HIV (December 2022)*
FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention (December 2021)
FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection (January 2021)
FDA Approves New HIV Treatment for Patients Who Have Limited Treatment Options (March 2018)*
FDA Approves Egrifta to Treat Lipodystrophy in HIV Patients (November 2010)*
* Press statement not available on FDA's websiteHIV+Hep Policy Institute
O’Neill Institute for National and Global Health Law at Georgetown University
Positively Aware Magazine
Guide to Long-Acting Injectables for HIV (August 2024)
Attitudes and Access: Survey Results on Long-Acting Injectables for HIV (June 2024)
BACK TO TOPCommittee Resources
This project is funded by the following corporate entities:
Gilead Sciences, Merck, and ViiV Healthcare.
Transparency statement:
To read our Transparency Statement, click here.
BACK TO TOP